Abstract
The human herpesviruses herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) can cause severe recurrent disease in humans and establish lifelong infection in their hosts. Several antiviral therapies are available to control disease and spread, but these are not completely effective and do not affect latent virus. The need for vaccines for HSV is urgent, both for controlling initial infection and spread of disease as well as to limit recurrences. Several approaches including subunit vaccines, peptide vaccines, live virus vectors and DNA vaccine technology have been used in developing both prophylactic and therapeutic vaccines for HSV and these are reviewed here.
Keywords: interferons, adaptive immune response, Peptide Vaccines, disabled infectious single cycle viruses, HSV DNA, Live Virus Vaccines
Current Pharmaceutical Design
Title: Potential Prophylactic and Therapeutic Vaccines for HSV Infections
Volume: 13 Issue: 19
Author(s): Srividya Ramachandran and Paul R. Kinchington
Affiliation:
Keywords: interferons, adaptive immune response, Peptide Vaccines, disabled infectious single cycle viruses, HSV DNA, Live Virus Vaccines
Abstract: The human herpesviruses herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) can cause severe recurrent disease in humans and establish lifelong infection in their hosts. Several antiviral therapies are available to control disease and spread, but these are not completely effective and do not affect latent virus. The need for vaccines for HSV is urgent, both for controlling initial infection and spread of disease as well as to limit recurrences. Several approaches including subunit vaccines, peptide vaccines, live virus vectors and DNA vaccine technology have been used in developing both prophylactic and therapeutic vaccines for HSV and these are reviewed here.
Export Options
About this article
Cite this article as:
Srividya Ramachandran and Paul R. Kinchington , Potential Prophylactic and Therapeutic Vaccines for HSV Infections, Current Pharmaceutical Design 2007; 13 (19) . https://dx.doi.org/10.2174/138161207781039760
DOI https://dx.doi.org/10.2174/138161207781039760 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Risk of Cervical Cancer After HPV Vaccination
Current Pharmaceutical Design Therapeutic Targets for the Management of Peripheral Nerve Injury- Induced Neuropathic Pain
CNS & Neurological Disorders - Drug Targets Detection of Tumor Markers with ProteinChip® Technology
Current Pharmaceutical Biotechnology Interplay between Epigenetics & Cancer Metabolism
Current Pharmaceutical Design The DNA-Binding and Bioactivity of Rare Earth Metal Complexes
Mini-Reviews in Medicinal Chemistry A Proteomics Study of the Subacute Toxicity of Rat Brain after Long- Term Exposure of <i>Gelsemium elegans</i>
Current Molecular Pharmacology Breast Cancer Diagnosis Using Data Mining Methods, Cumulative Histogram Features, and Gary Level Co-occurrence Matrix
Current Medical Imaging Advances in Synergistic Combinations of Chinese Herbal Medicine for the Treatment of Cancer
Current Cancer Drug Targets Pharmacology of Rhein and Advancement in the Synthesis of Its Derivatives
Current Traditional Medicine HLA Associations with Nasopharyngeal Carcinoma
Current Molecular Medicine Notch Inhibitors as a New Tool in the War on Cancer: A Pathway to Watch
Current Pharmaceutical Biotechnology Involvement of Cannabinoids in Cellular Proliferation
Mini-Reviews in Medicinal Chemistry Targeting miRNAs for Pancreatic Cancer Therapy
Current Pharmaceutical Design Structure-Activity Relationship Studies on Holy Basil (Ocimum sanctum L.) Based Flavonoid Orientin and its Analogue for Cytotoxic Activity in Liver Cancer Cell Line HepG2
Combinatorial Chemistry & High Throughput Screening Biomarkers to Assess the Targeting of DNA Repair Pathways to Augment Tumor Response to Therapy
Current Molecular Medicine Patent Selections
Recent Patents on Anti-Cancer Drug Discovery New Perspectives in the Pharmacological Treatment of Non-Melanoma Skin Cancer
Current Drug Targets Crocetin: an Agent Derived from Saffron for Prevention and Therapy for Cancer
Current Pharmaceutical Biotechnology Biomedical Applications of Zinc Oxide Nanomaterials
Current Molecular Medicine Targeting Cancer Cells with Photoactive Silica Nanoparticles
Current Pharmaceutical Design